Figure 1
Figure 1. Serum ferritin, LIC, and actual dose in cohorts for patients with ≥ 4 years of deferasirox exposure. Median serum ferritin ± range, mean LIC ± SD (biopsy), and mean actual dose ± SD in (A) the deferasirox cohort and (B) the crossover cohort for patients with ≥ 4 years of deferasirox exposure by planned starting dose category ≤ 10, 20, or 30 mg/kg/day. Only patients with ≥ 4 years of exposure to deferasirox are included. LIC values are for patients assessed by biopsy at start of deferasirox and at EOS, whereby EOS represents the last available biopsy assessment occurring after ≥ 4 years of exposure to deferasirox. Patients with LIC assessments by SQUID are not included in this figure. One crossover cohort patient included in the ≤ 10 mg/kg/day category had a planned starting dose of 15 mg/kg/day. Error bars indicate the minimum and maximum values for the serum ferritin plot and the SD for both the LIC and dose plots.

Serum ferritin, LIC, and actual dose in cohorts for patients with ≥ 4 years of deferasirox exposure. Median serum ferritin ± range, mean LIC ± SD (biopsy), and mean actual dose ± SD in (A) the deferasirox cohort and (B) the crossover cohort for patients with ≥ 4 years of deferasirox exposure by planned starting dose category ≤ 10, 20, or 30 mg/kg/day. Only patients with ≥ 4 years of exposure to deferasirox are included. LIC values are for patients assessed by biopsy at start of deferasirox and at EOS, whereby EOS represents the last available biopsy assessment occurring after ≥ 4 years of exposure to deferasirox. Patients with LIC assessments by SQUID are not included in this figure. One crossover cohort patient included in the ≤ 10 mg/kg/day category had a planned starting dose of 15 mg/kg/day. Error bars indicate the minimum and maximum values for the serum ferritin plot and the SD for both the LIC and dose plots.

Close Modal

or Create an Account

Close Modal
Close Modal